{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:05:14Z","timestamp":1793390714995,"version":"4.5.0"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T00:00:00Z","timestamp":1720828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007775","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007775","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","nmd-journal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.nmd.2024.07.002","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T13:02:50Z","timestamp":1720616570000},"page":"39-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Ocular versus generalized myasthenia gravis: a continuum associated with acetylcholine receptor antibody titers"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2246-7351","authenticated-orcid":false,"given":"Kasper Holst","family":"Axelsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Kj\u00e6r Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda Kahr","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Vissing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanna","family":"Witting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2024.07.002_bib0001","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2024.07.002_bib0002","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaut.2014.01.003","article-title":"Diagnostic and clinical classification of autoimmune myasthenia gravis","volume":"48\u201349","author":"Berrih-Aknin","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.nmd.2024.07.002_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.605902","article-title":"Controversies in ocular myasthenia gravis","volume":"11","author":"Evoli","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.nmd.2024.07.002_bib0004","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/ene.12359","article-title":"EFNS\/ENS Guidelines for the treatment of ocular myasthenia","volume":"21","author":"Kerty","year":"2014","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nmd.2024.07.002_bib0005","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.revmed.2013.09.012","article-title":"Myasth\u00e9nie et auto-anticorps : physiopathologie des diff\u00e9rentes entit\u00e9s","volume":"35","author":"Berrih-Aknin","year":"2014","journal-title":"La Revue de M\u00e9decine Interne"},{"key":"10.1016\/j.nmd.2024.07.002_bib0006","doi-asserted-by":"crossref","first-page":"985","DOI":"10.4103\/0301-4738.145987","article-title":"Ocular myasthenia gravis: a review","volume":"62","author":"Nair","year":"2014","journal-title":"India J Ophthalmol"},{"key":"10.1016\/j.nmd.2024.07.002_bib0007","unstructured":"Andersen H., Gaist D., Hansen K., H\u00f8jgaard J.L.S. & Vissing J. Retningslinjer for myastenibehandlingen i Danmark 2017. 41. https:\/\/nnbv.dk\/myasthenia-gravis-behandling\/ (accessed 10 March 2024)."},{"key":"10.1016\/j.nmd.2024.07.002_bib0008","doi-asserted-by":"crossref","first-page":"965","DOI":"10.29271\/jcpsp.2021.08.965","article-title":"Relationship between low and high anti-acetylcholine receptor antibody titers and clinical severity in Myasthenia Gravis","volume":"31","author":"Ullah","year":"2021","journal-title":"J Coll Physic Surg Pak"},{"key":"10.1016\/j.nmd.2024.07.002_bib0009","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/jnnp.56.5.496","article-title":"Clinical implementation of anti-acetylcholine receptor antibodies","volume":"56","author":"Somnier","year":"1993","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nmd.2024.07.002_bib0010","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/archneurol.2012.437","article-title":"Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized Myasthenia Gravis","volume":"69","author":"Jacob","year":"2012","journal-title":"Arch Neurol (Chicago)"},{"key":"10.1016\/j.nmd.2024.07.002_bib0011","first-page":"345","article-title":"Myasthenia gravis: MuSK MG, late-onset MG and ocular MG","volume":"39","author":"Deymeer","year":"2020","journal-title":"Acta Myologica"},{"key":"10.1016\/j.nmd.2024.07.002_bib0012","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/mus.27103","article-title":"Autoantibodies in Japanese patients with ocular myastheni a gravis","volume":"63","author":"Nagaishi","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2024.07.002_bib0013","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ana.410210309","article-title":"Heterogeneity in myasthenia gravis: HLA phenotypes and autoantibody responses in ocular and generalized types","volume":"21","author":"Kida","year":"1987","journal-title":"Ann Neurol"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896624001433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896624001433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T14:12:14Z","timestamp":1729519934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896624001433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":13,"alternative-id":["S0960896624001433"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2024.07.002","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular versus generalized myasthenia gravis: a continuum associated with acetylcholine receptor antibody titers","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2024.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}